Royalty Pharma plc
RPRX
Positions held
Your positionsRPRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Royalty Pharma operates in the biotechnology sector, which is experiencing a robust growth cycle driven by increasing demand for innovative therapies and treatments.
- Revenue increased by 7% compared to the prior quarter, reaching $674 million.
- The company has a strong profit margin of 32.02%.
- The company's earnings growth has declined significantly, with a decrease of 46.3% year-over-year.
- The operating margin has compressed to 19.7%, indicating potential challenges in maintaining profitability.
- The stock has a strong sell signal with a score of -28.00, reflecting bearish market sentiment.
Fundamentals
| Market cap | $32.48B | Enterprise value | $36.11B | Trailing P/E | 29.90 | Forward P/E | 9.80 |
| PEG | 1.32 | Price / book | 3.67 | Beta | 0.41 | Dividend yield | 1.67% |
| Revenue growth | 16.5% | Earnings growth | -46.3% | Gross margin | 95.8% | Operating margin | 19.7% |
| Profit margin | 32.0% | ROE | 14.0% | ROA | 5.1% | Debt / equity | 0.92 |
| Current ratio | 2.80 | Free cash flow | -$1.20B | Analyst recommendation | strong_buy | Mean target | $65.38 |
| 52w high | $64.38 | 52w low | $35.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $674M | $631M | $622M | $609M | $579M | — |
| Op margin | 19.7% | 100.3% | 62.4% | 70.1% | 36.3% | — |
| Net income | $17.9M | $295M | $214M | $288M | $32.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | $133M | $632M | $388M | $427M | $210M | — |
- Revenue +7% vs prior quarter ($674M vs $631M).
- Operating margin compressed to 19.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.3B | $2.4B | $2.2B | — |
| Op margin | 65.6% | 57.1% | 63.4% | 41.3% | — |
| Net income | $771M | $859M | $1.1B | $42.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $1.6B | $1.3B | $1.5B | $923M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
2026-10-01 · Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
2026-09-25 · Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
2026-09-25 · Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
2026-09-23 · Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
2026-09-23 · Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
2026-09-15 · Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
2026-09-15 · Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
2026-09-10 · Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
2026-09-09 · Royalty Pharma to present at upcoming investor conferences
2026-09-09 · Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
2026-09-08 · Royalty Pharma Shares Fall After Novartis' Pelacarsen Fails Trial
Price (daily)
Full chart · RSI · MACD · patterns